WRWilliam L. Read

William L. Read

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


William L. Read has a total of 58 co-authors. Here are the top co-authors by number of shared publications:

  • Felicia Williams

    Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA

    4 shared publications
  • Kevin T. Brumund

    Moores Cancer Center, UC San Diego Health System, La Jolla, California

    2 shared publications
  • Ahmed Idbaih

    Sorbonne Université, AP-HP, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neuro-Oncologie-Institut de Neurologie, F-75013, Paris, France

    1 shared publication
  • Amy E. Wahlquist

    Cancer Center Medical University of South Carolina Charleston South Carolina

    1 shared publication
  • Andrea Salmaggi

    Department of Neurology and Stroke Unit, ASST Lecco Ospedale Alessandro Manzoni, Lecco, Italy

    1 shared publication
  • Andreas Felix Hottinger

    Lundin Family Brain Tumor Research Centre, Departments of Oncology & Clinical Neurosciences, University Hospital Lausanne and University of Lausanne, Lausanne, Switzerland

    1 shared publication

Latest Publications

  • Open Access

    DDDR-14. YAP/TAZ TRANSCRIPTIONAL CO-ACTIVATORS DRIVE NEURO-GLIAL STEM/PROGENITOR CELL IDENTITY IN HIGH GRADE GLIOMAS

    by Renee Read, Se-Yeong Oh, Krishanthan Vigneswaran, Nathaniel Boyd, Elizabeth Young, William Read, Jeffrey Olson

    High-grade gliomas (HGGs), neoplasms derived from neuro-glial stem/progenitor cells, are the most common and lethal malignant primary brain tumors diagnosed in adults and children, with a median survival time of 14 months with current treatments. HGG tumorigenicity is often driven by genetic aberrations in receptor tyrosine kinases (RTKs), such as EGFR, and the Pi-3 kinase (PI3K) signaling pathway. Using Drosophila, mouse, and human HGG model systems of RTK-PI3K mutant HGGs, we identified the YAP and TAZ transcription co-activators, which regulate gene expression via TEAD co-factors, as key drivers of HGG tumorigenicity downstream of oncogenic RTK signaling. YAP and TAZ are highly expressed in RTK-mutant human HGG cells, and regulate TEAD-mediated transcription of several transcription factors, neurodevelopmental genes, and receptors, including the EGFR RTK, that together create a feedforward loop with RTKs to maintain a radial-glia-like stem/progenitor cell fate in HGG cells. Inhibition of YAP and TAZ in self-renewing stem-cell-like RTK mutant HGG cells can inhibit proliferation, block stem/progenitor cell fate, and elicit apoptosis. In particular, the benzoporphyrin derivative verteporfin, a disruptor of YAP/TAZ-TEAD mediated transcription, specifically induced apoptosis of cultured patient-derived HGG cells, suppressed expression of YAP/TAZ transcriptional targets, including RTKs, and conferred significant survival benefit in an orthotopic xenograft HGG model. Our efforts led us to initiate phase 0 and phase 1/2 clinical trials of Visudyne, an FDA-approved liposomal formulation of verteporfin, in which we have verified verteporfin uptake into tumor cells and are now testing the therapeutic efficacy of verteporfin in human patients. Finally, we have examined mechanisms of response and resistance to verteporfin, and we have evidence that stem-like HGG cells can escape the effects of YAP/TAZ inhibition by recapitulating neuro-glial developmental cell fate transitions. Together, our data indicate that targeting YAP/TAZ functionality is a promising therapeutic approach for HGG.

  • A randomized, open‐label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft‐tissue sarcoma

    by Neeta Somaiah, Brian Andrew Van Tine, Amy E. Wahlquist, Mohammed M. Milhem, Elizabeth G. Hill, Elizabeth Garrett‐Mayer, Kent E. Armeson, Scott M. Schuetze, Christian F. Meyer, Daniel Y. Reuben, et al.

    Background: Therapeutic options for patients with advanced soft‐tissue sarcoma (STS) are limited. The goal of the current phase 2 study was to examine the clinical activity and safety of the combination of gemcitabine plus pazopanib, a multityrosine kinase inhibitor with activity in STS.Methods: The current randomized, phase 2 trial enrolled patients with advanced nonadipocytic STS who had received prior anthracycline‐based therapy. Patients were assigned 1:1 to receive gemcitabine at a dose of 1000 mg/m2 on days 1 and 8 with pazopanib at a dose of 800 mg daily (G+P) or gemcitabine at a dose of 900 mg/m2 on days 1 and 8 and docetaxel at a dose of 100 mg/m2 on day 8 (G+T) every 3 weeks. Crossover was allowed at the time of disease progression. The study used a noncomparative statistical design based on the precision of 95% confidence intervals for reporting the primary endpoints of median progression‐free survival (PFS) and rate of grade ≥3 adverse events (AEs) for these 2 regimens based on the intent‐to‐treat patient population (AEs were graded using version 4.0 of the National Cancer Institute Common Terminology Criteria for Adverse Events).Results: A total of 90 patients were enrolled: 45 patients on each treatment arm. The median PFS was 4.1 months for each arm (P = .3, log‐rank test). The best overall response of stable disease or better (complete response + partial response + stable disease) was the same for both treatment arms (64% for both the G+T and G+P arms). The rate of related grade ≥3 AEs was 82% for the G+T arm and 78% for the G+P arm. Related grade ≥3 AEs occurring in ≥10% of patients in the G+T and G+P arms were anemia (36% and 20%, respectively), fatigue (29% and 13%, respectively), thrombocytopenia (53% and 49%, respectively), neutropenia (20% and 49%, respectively), lymphopenia (13% and 11%, respectively), and hypertension (2% and 20%, respectively).Conclusions: The data from the current study have demonstrated the safety and efficacy of G+P as an alternative to G+T for patients with nonadipocytic STS.


  • Open Access

    Recurrent Epithelioid Hemangioma of the Bony Pelvis Responding to Propranolol

    by Sam Broida, Nickolas Reimer, William L. Read

    Epithelioid hemangioma is an uncommon benign vascular neoplasm which can arise in bone. Resection is generally curative, but occasionally lesions recur and recurrence after surgery can be morbid and destructive. Recent case reports have described the effective use of oral propranolol to control recurrent epithelioid hemangioma of the orbit. We report the case of a 26 year old man with recurrent aggressive osseous epithelioid hemangioma in the pelvis of which has been controlled for over a year with outpatient propranolol monotherapy.


  • Open Access

    The use of a predictive statistical model to make a virtual control arm for a clinical trial

    by Jeffrey M. Switchenko, Arielle L. Heeke, Tony C. Pan, William L. Read

    Randomized clinical trials compare participants receiving an experimental intervention to participants receiving standard of care (SOC). If one could predict the outcome for participants receiving SOC, a trial could be designed where all participants received the experimental intervention, with the observed outcome of the experimental group compared to the prediction for those individuals. We used the CancerMath calculator to predict outcomes for participants in two large clinical trials of adjuvant chemotherapy for breast cancer: NSABPB15 and CALGB9344. NSABPB15 was the training set, and we used the modified algorithm to predict outcomes for two groups from CALGB9344: one which received standard of care (SOC) chemotherapy and one which received paclitaxel in addition. We made a prediction for each individual CALGB9344 participant, assuming each received only SOC. The predicted outcome for the group which received only SOC matched what was observed in the CALGB9344 trial. In contrast, the predicted outcome for the group also receiving paclitaxel was significantly worse than what was observed for this group. This matches the conclusion of CALGB9344 that adding paclitaxel to SOC improves survival. This project proves that a statistical model can predict the outcome of clinical trial participants treated with SOC. In some circumstances, a predictive model could be used instead of a control arm, allowing all participants to receive experimental treatment. Predictive models for cancer and other diseases could be constructed using the vast amount of outcomes data available to the federal government, and made available for public use.


  • Open Access

    Recurrent Meningioma of the Cervical Spine, Successfully Treated with Liposomal Doxorubicin

    by William L. Read, Felicia Williams

    There is no standard systemic treatment for persons with recurrent meningioma who have exhausted surgery and radiation options. Liposomal doxorubicin is a cytotoxic chemotherapy which is sustainable and tolerable, with activity against a range of solid tumors. There exists one reported case of metastatic meningioma effectively treated with liposomal doxorubicin. We report a second case. Our patient, a 35-year-old man with recurrent meningioma compressing the cervical spinal cord received liposomal doxorubicin for 22 months with clinical improvement, minimal toxicity, and slow regression of his tumor. He is well and without progression 18 months after stopping chemotherapy and 4 years after his last progression event.


  • Open Access

    LTBK-01: PROSPECTIVE, MULTI-CENTER PHASE III TRIAL OF TUMOR TREATING FIELDS TOGETHER WITH TEMOZOLOMIDE COMPARED TO TEMOZOLOMIDE ALONE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA

    by Roger Stupp, Ahmed Idbaih, David M. Steinberg, William Read, Steven Toms, Gene Barnett, Garth Nicholas, Chae-Yong Kim, Karen Fink, Andrea Salmaggi, et al.

    Tumor Treating Fields (TTFields) is an established, frequency-tuned, anti-mitotic, physical treatment modality that acts in metaphase, anaphase and telophase. TTFields are delivered to the brain by a patient operated, portable medical device (Optune™, Novocure Ltd.). An international, multicenter, prospective, randomized phase 3 trial (EF-14) was initiated in 2009 to test the efficacy and safety of combining TTFields with temozlomide (TMZ) compared to TMZ alone following radiation therapy with adjuvant TMZ in patients with newly diagnosed GBM. Results of a protocol pre-specified successful interim analysis on the first 315 patients randomized has been reported (Stupp et al. JAMA 2015). Here we report the main outcomes of all 695 patients enrolled with a mature minimum follow-up of 18 month (median follow-up 36 months) for all patients (Range 19–80 months). Within 7 weeks after the end of TMZ/RT and stratification for extent of resection and MGMT status patients were randomized (at a 1:2 ratio) to either standard adjuvant TMZ alone (150–200 mg/m2/d x 5d) or TMZ and continuous administration of TTFields. Eligible patients had a newly diagnosed GBM, non-progressive after concomitant chemoradiotherapy, a performance status of ≥70%, and adequate hematological, liver and renal function. The primary endpoint of the study is progression free survival (PFS) as determined by blinded central radiology review; overall survival (OS) is a powered secondary endpoint. A total of 695 patients were randomized from 7/2009 – 11/2014. Patient characteristics are balanced, median age was 56 years (range 19–83), 87 % had undergone prior tumor resection and 13 % a biopsy only. 37% of tumors were MGMT methylated. Median time from end of radiotherapy to randomization was 37 days. The median number of adjuvant (maintenance) TMZ cycles 6 and 5 cycles, for TTFields/TMZ and TMZ alone, respectively. All analyses are intent-to-treat. The median progression-free survival was 6.7 months (95%CI 6.1–8.1) for the patients treated with TTFields/TMZ versus 4.0 months (CI 3.8 – 4.3) for TMZ alone (hazard ratio 0.63, pst line glioblastoma over a decade ago.


  • Open Access

    Metastatic Alveolar Soft Part Sarcoma Responsive to Pazopanib after Progression through Sunitinib and Bevacizumab: Two Cases

    by William L. Read, Felicia Williams

    Alveolar soft part sarcoma (ASPS) is a rare soft tissue sarcoma with a propensity for lung metastases and indolent progression. ASPS is not responsive to chemotherapy, but there are case reports and small series describing benefit from drugs targeting the VEGF pathway. These drugs include sunitinib, cediranib and bevacizumab. There is no established second-line treatment for persons with ASPS progressing through first-line targeted therapy. We report two individuals with metastatic ASPS who obtained disease stabilization from sunitinib lasting over a year. After subsequent progression through sunitinib and second-line bevacizumab, both individuals again had disease response and subsequent stabilization from pazopanib.


  • Open Access

    Metastatic Angiosarcoma with Kasabach-Merritt Syndrome Responsive to Gemcitabine and Vinorelbine after Failure of Liposomal Doxorubicin and Paclitaxel: A Case Report

    by William L. Read, Felicia Williams

    Kasabach-Merritt syndrome (KMS) describes a consumptive coagulopathy associated with certain vascular tumors. It is thought that platelets are destroyed as they circulate through the aberrant endothelial surfaces associated with these tumors. Most published literature describes infants with kaposiform hemangioendothelioma, but a similar syndrome can complicate angiosarcoma in adults. This report describes a man with metastatic angiosarcoma arising in the scalp in whom disease progression was complicated by profound thrombocytopenia consistent with KMS. His disease and associated KMS had progressed previously through paclitaxel and then through liposomal doxorubicin. It did not respond to paclitaxel and bevacizumab, but responded almost completely to chemotherapy with gemcitabine and vinorelbine. Six months later, progression through ongoing chemotherapy then responded to chemotherapy with cyclophosphamide and sirolimus.


  • Open Access

    Squamous cell carcinomas of the skin responsive to erlotinib: 5 cases

    by William L. Read, Kevin T. Brumund, Robert A. Weisman, Angel Q. Nguyen